Hematology:

In the last seven days, 290 new articles where published in 25 top journals in the field of hematology.

Major topics on this page:

Blood | Review | 2025 Apr 3

Classification and risk stratification in T-lineage acute lymphoblastic leukemia.

Pölönen P and Others

Cure rates for patients with acute lymphoblastic leukemia (ALL) have improved markedly in recent decades, in part because of risk stratification incorporating leukemia genomics, response to treatment, and clinical features to be able to determine at diagnosis which patients are more likely to relapse or have refractory disease. Although risk stratification is well developed for patients with B-lineage ALL, it remains challenging for those with T-lineage ALL (T-ALL). Prognostic factors validated across clinical trials and real-world data in T-ALL include age, central nervous system involvement, and measurable residual disease (MRD) response. Immunophenotype, including early T-cell precursor ALL, is widely used to classify T-ALL but is not consistently associated with outcome in multivariable risk models. Historically, few genetic alterations have been consistently associated with outcome, but recent comprehensive, large-scale genomic profiling has identified multiple genetic subtypes and alterations associated with outcome independent of MRD. This review highlights ongoing efforts to identify reliable prognostic biomarkers and underscores the potential of genomics-based classification to guide future T-ALL treatment strategies.

Haematologica | Journal Article | 2025 Apr 3

Risk of leukemia in twins.

Greaves M

Not available.

American journal of hematology | Journal Article | 2025 Apr

Hyperparathyroidism and the Hematologist.

Oun H and Others

No abstract available

Arteriosclerosis, thrombosis, and vascular biology | News | 2025 Apr

ATVB Journal Awards at Vascular Discovery.

Schmidt AM

No abstract available

Blood | Review | 2025 Apr 3

The present and future of CAR T-cell therapy for adult B-cell ALL.

Rampotas A and Others

Chimeric antigen receptor T-cell therapy (CAR-T) targeting CD19 has transformed the management of relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), with the US Food and Drug Administration approval of tisagenlecleucel for pediatric/young adult patients and brexucabtagene autoleucel for adults. Efficacy is contingent upon several factors including disease burden. Emerging data suggest that bridging therapy, lymphodepletion, and, for some patients, consolidation therapy have an important role in the success of treatment. Furthermore, strategies to define and manage immunotoxic side effects including hematotoxicity is critical to safe delivery. Advancements in CAR-T design beyond CD19 represent an ongoing therapeutic evolution. Overall, CAR-T signifies a paradigm shift in B-ALL management, with the potential for improved remission and survival in a historically challenging patient population.

American journal of hematology | Letter | 2025 Apr

Prospective Pharmacokinetic Evaluation of Venetoclax in AML Supports Re-Evaluation of Recommended Dose Adjustments With Azole Antifungals.

Kawedia JD and Others

No abstract available

The Lancet. Haematology | Journal Article | 2025 Apr

Peripheral T-cell lymphoma in the Latin American population.

Domingo Domenech E

No abstract available

Haematologica | Journal Article | 2025 Apr 1

Primary myelofibrosis progression: a game of cellular telephone.

Wadley L and Others

No abstract available

The Lancet. Haematology | Journal Article | 2025 Apr

CAR T-cell therapy in LMICs: approval of talicabtagene autoleucel in India.

Paruzzo L and Others

No abstract available

American journal of hematology | Letter | 2025 Apr

A Case of Hodgkin Lymphoma in a Gaucher Disease Patient: Distinguishing Gaucher and Pseudo-Gaucher Cells.

Scaramellini N and Others

No abstract available

Haematologica | Journal Article | 2025 Apr 1

Depletion of the RNA binding protein QKI and circular RNA dysregulation in T-cell acute lymphoblastic leukemia.

Buratin A and Others

No abstract available

The Lancet. Haematology | Journal Article | 2025 Apr

Now where do we STAND with crizanlizumab?

Mendez-Marti S and Others

No abstract available

American journal of hematology | Letter | 2025 Apr

Impact of Pre-Treatment Comorbidity Burden on Survival in Patients Receiving Venetoclax Plus Hypomethylating Agents.

Marconi G and Others

Expectation of survival of patients receiving HMA + VEN is influenced by pre-treatment comorbidity burden.

The Lancet. Haematology | Published Erratum | 2025 Apr

Correction to Lancet Haematol 2025; 12: e128-37.

No authors listed

No abstract available

The Lancet. Haematology | Published Erratum | 2025 Apr

Correction to Lancet Haematol 2025; 12: e120-27.

No authors listed

No abstract available